In an "Executive Decision" segment, Cramer sat down for a conversation with Chris Viehbacher, CEO of drug-maker Sanofi (SNY), another Action Alerts PLUS stock that's been hit hard thanks to the European contagion.
Viehbacher said that its clear that investors aren't paying close attention to the fundamentals at the moment, as none of the company's fundamentals has changed. He said that Sanofi is still committed to rewarding shareholders, which is why the company increased its dividend payout ratio and why he personally as purchased Sanofi stock recently.
Regarding the company's upcoming patent expirations, Viehbacher said he's tired of playing the "cat-and-mouse" game with investors and has opted to tell it like it is. He said that patents do expire and they do hurt a company's bottom line, but there is nothing they can do about it. Viehbacher said this will be his fourth "patent cliff," and Sanofi will continue to grow, even through the decline.Among the bright spots has been Sanofi's acquisition of Genzyme. Viehbacher noted that biotech products have a better probably of success through research and development and they also aren't as impacted by generics since the drugs they produce are difficult to produce. Other bright spots for the company included Sanofi's diabetes business, where the company is one of only two major players in the insulin market, as well as a drug for MS, which is seeing success in trials with only eight treatments over an 8-week period, followed by three treatments a year later. Viehbacher said patients on that regiment are seeing no relapses 60% of the time. Finally, when asked about how government price controls are affecting the company, Viehbacher said that less than a third of Sanofi's business is subject to price controls, and the company is working to further diversify into other areas to avoid such pressures. Cramer continued his recommendation for Sanofi, calling the company's European-induced slide the perfect buying opportunity.